


The New Age of Alzheimer's Disease Therapeutics



Virtual Continuing Medical Education Conference

Saturday, April 12, 2025 | www.ccfcmc.org/NAADT25

CONFERENCE OVERVIEW

PROGRAM DESCRIPTION

The introduction of anti-amyloid therapies as a new class of treatment for Alzheimer's Disease (AD) has brought significant advances in the care of patients with mild cognitive impairment (MCI) and early-stage AD. However, healthcare providers, especially neurologists, face numerous challenges in integrating these therapies into clinical practice. These include uncertainties regarding patient selection, pre-authorization and insurance processes, infusion logistics, management of potential side effects like ARIA (amyloid-related imaging abnormalities), and determining the appropriate duration and frequency of treatment.

The goal of this CME program is to provide healthcare professionals with the necessary tools, knowledge, and resources to confidently navigate these challenges. The conference will address critical aspects of anti-amyloid therapies in clinical practice, including cognitive assessment, patient selection, the pre-authorization process, infusion logistics, and the management of side effects like ARIA.

This conference will also foster greater collaboration between neurologists and primary care physicians (PCPs), enabling early recognition and screening for AD and MCI, ultimately improving patient outcomes by accelerating the anti-amyloid treatment process.

TARGET AUDIENCE

This CME activity is designed for neurologists, primary care physicians (PCPs), internists, geriatricians, nurse practitioners, nurses, physician assistants (PAs), and other healthcare providers involved in the diagnosis, management, and treatment of patients with Alzheimer's Disease or MCI.

REGISTRATION

Fees

Physicians \$30

Non-Physicians \$30

Registration fee includes downloadable syllabus/program

REGISTRATION

Register now: ccfme.org/NAAD25

Preregistration is accepted until 3:00 pm (PST) Friday, April 11, 2025.

Questions? 216.448.8710 or cmeregistration@ccf.org

CANCELLATION

A full refund will be made if email notification is received by April 11, 2025 at 3:00 PM PST. NO REFUNDS AFTER April 11.

CONFERENCE VENUE

Virtual: Link will be sent upon registration.

Contact: LeeAnn Mandarino, 702.483.6024

ACCREDITATION

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

• American Medical Association (AMA)

Cleveland Clinic Center for Continuing Education designates this internet live activity for a maximum of 3 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

• American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this internet live activity for a maximum of 3 ANCC contact hours.

• Certificate of Participation

A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

FACULTY DISCLOSURE STATEMENT:

The Cleveland Clinic Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

AMERICANS WITH DISABILITIES ACT

The Cleveland Clinic Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify LeeAnn Mandarino at 702.483.6024 at least two weeks prior to the activity.

AGENDA

9:00 – 9:20 AM	Welcome Pre-test Background on anti-amyloid therapies Charles Bernick, MD, MPH
9:20 – 9:50 AM	Translating clinical trial results to the clinic Babak Tousi, MD
9:50 – 10:20 AM	Who is the right patient for anti-amyloid therapies? Lakeshia Gibson, MD
10:20 – 10:30 AM	Break
10:30 – 11:30 AM	Surveillance for amyloid-related imaging abnormalities (ARIA) Dylan Wint, MD
11:30 – 12:00 PM	Logistics of starting anti-amyloid therapy Maileen Ulep, PhD, MSN, APRN, FNP-BC
12:00 – 12:10 PM	Conclusion Post-test Adjourn

5 minutes will be provided for Q&A after each presentation

All times are Pacific Daylight Time (PDT)

LEARNING OBJECTIVES

Upon completion of this program, participants will be able to:

1. Describe the clinical effects of anti-amyloid therapies and be able to convey to patients.
2. Identify patients that are candidates for anti-amyloid therapies.
3. Recognize and monitor the potential complications of anti-amyloid therapies.
4. List the administrative steps necessary to prescribe anti-amyloid therapies.

CLEVELAND CLINIC FACULTY

COURSE DIRECTOR

Charles Bernick, MD, MPH

Senior Director, Cognitive Disorders

Lou Ruvo Center for Brain Health, Las Vegas, NV

PRESENTERS

Lakeshia Gibson, MD

Staff Physician | Psychiatrist | Cognitive Disorders

Lou Ruvo Center for Brain Health, Las Vegas, NV

Babak Tousi, MD

Staff Physician | Neurogeriatrician

Lou Ruvo Center for Brain Health, Lakewood, OH

Dylan Wint, MD

Center Director | Camille and Larry Ruvo Endowed Chair for Brain Health
Director of Education | Las Vegas Legacy Endowed Chair for Neuroscience Education

Director, Fellowship in Behavioral Neurology and Neuropsychiatry

Lou Ruvo Center for Brain Health, Las Vegas, NV

PLANNING COMMITTEE

Maileen Ulep, PhD, MSN, APRN, FNP-BC

Nurse Practitioner | Cognitive Disorders

Lou Ruvo Center for Brain Health, Las Vegas, NV